Raubitschek AA - Search Results

1

The two types of correction of absorbed dose estimates for internal emitters.

Williams LE, Liu A, Yamauchi DM, Lopatin G, Raubitschek AA, Wong JY. Williams LE, et al. Among authors: raubitschek aa. Cancer. 2002 Feb 15;94(4 Suppl):1231-4. doi: 10.1002/cncr.10290. Cancer. 2002. PMID: 11877750 Free article.

2

Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.

Odom-Maryon TL, Williams LE, Chai A, Lopatin G, Liu A, Wong YC, Chou J, Clarke KG, Raubitschek AA. Odom-Maryon TL, et al. Among authors: raubitschek aa. J Nucl Med. 1997 Dec;38(12):1959-66. J Nucl Med. 1997. PMID: 9430477 Free article. Clinical Trial.

3

Estimating residence times and their associated errors in patient absorbed-dose calculation.

Kaplan DD, Williams LE, Clarke KG, Odom-Maryon TL, Liu A, Lopatin G, Raubitschek AA, Wong JY. Kaplan DD, et al. Among authors: raubitschek aa. J Nucl Med Technol. 1997 Dec;25(4):264-8. J Nucl Med Technol. 1997. PMID: 9438927

4

A radionuclide therapy treatment planning and dose estimation system.

Liu A, Williams LE, Lopatin G, Yamauchi DM, Wong JY, Raubitschek AA. Liu A, et al. Among authors: raubitschek aa. J Nucl Med. 1999 Jul;40(7):1151-3. J Nucl Med. 1999. PMID: 10405136 Free article.

5

A method for patient-specific absorbed dose estimation for internal beta emitters.

Williams LE, Liu A, Raubitschek AA, Wong JY. Williams LE, et al. Among authors: raubitschek aa. Clin Cancer Res. 1999 Oct;5(10 Suppl):3015s-3019s. Clin Cancer Res. 1999. PMID: 10541337

6

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA. Wong JYC, et al. Among authors: raubitschek aa. Clin Cancer Res. 2000 Oct;6(10):3855-63. Clin Cancer Res. 2000. PMID: 11051230 Clinical Trial.

7

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE. Crow DM, et al. Bioconjug Chem. 2005 Sep-Oct;16(5):1117-25. doi: 10.1021/bc0500948. Bioconjug Chem. 2005. PMID: 16173788

8

Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.

Bading JR, Hörling M, Williams LE, Colcher D, Raubitschek A, Strand SE. Bading JR, et al. Cancer Biother Radiopharm. 2008 Aug;23(4):399-409. doi: 10.1089/cbr.2007.0457. Cancer Biother Radiopharm. 2008. PMID: 18771344 Free PMC article.

9

A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Wong JY, Raubitschek A, Yamauchi D, Williams LE, Wu AM, Yazaki P, Shively JE, Colcher D, Somlo G. Wong JY, et al. Cancer Biother Radiopharm. 2010 Aug;25(4):387-94. doi: 10.1089/cbr.2010.0783. Cancer Biother Radiopharm. 2010. PMID: 20707718 Free PMC article.

10

Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.

Cahan B, Leong L, Wagman L, Yamauchi D, Shibata S, Wilzcynski S, Williams LE, Yazaki P, Colcher D, Frankel P, Wu A, Raubitschek A, Shively J, Wong JYC. Cahan B, et al. Cancer Biother Radiopharm. 2017 Sep;32(7):258-265. doi: 10.1089/cbr.2017.2223. Cancer Biother Radiopharm. 2017. PMID: 28910150 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters